Align Technology (ALGN) is back in focus after its Q1 2026 earnings release, reaffirmed guidance, and a fresh wave of clear aligner and digital workflow product updates previewed at the AAO 2026 orthodontics conference.

Despite the Q1 2026 earnings beat, reaffirmed guidance, and product updates previewed around AAO 2026, the stock’s 1-day share price return of 3.19% decline and 7-day share price return of 4.33% decline suggest some near term caution. The year to date share price return of 7.92% sits against a 1-year total shareholder return of 6.93% decline and a 5-year total shareholder return of 69.58% decline, indicating that earlier long term momentum has faded.

If Align’s digital orthodontics push has your attention, it could be a good moment to broaden your watchlist and check out 35 healthcare AI stocks

With the stock down sharply from its multi year highs, yet trading at a discount to analyst targets and some intrinsic value models, the key question now is simple: is Align undervalued or is the market already pricing in future growth?

Most Popular Narrative: 8.9% Overvalued

The most followed narrative puts Align Technology’s fair value at $154.62, below the last close of $168.39, and frames the stock as a test of premium orthodontics in a tighter spending environment.

Align Technology is no longer proving that clear aligners work. It is proving that premium orthodontics can endure in a cost-sensitive world. For investors, ALGN represents a business built on medical credibility as much as consumer appeal. If Align continues to align innovation with clinical rigor, it may retain its leadership not through price competition, but through outcomes that justify the premium.

Want to see what sits behind that premium stance? The narrative leans on measured revenue gains, steady margin assumptions, and a valuation multiple more often linked with higher growth profiles.

Result: Fair Value of $154.62 (OVERVALUED)

However, this premium case could be challenged if lower cost competitors win share faster than expected or if consumer spending weakens further on elective treatments.

Another View: DCF Points To Deep Value

That 8.9% overvaluation call sits awkwardly next to our DCF model, which puts fair value at $275.69 per share versus the current $168.39. On that math, Align trades about 38.9% below the model. This raises the question: is sentiment too cautious, or are the cash flow assumptions too generous?

Next Steps

After weighing cautious sentiment against potential upside, this is the moment to move quickly. Review the underlying data yourself and consider both sides of the story with the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If Align has sharpened your focus on quality, do not stop here. Broaden your opportunity set with a few carefully filtered stock ideas that deserve attention.

• Target potential mispricings by scanning companies that combine quality fundamentals with attractive valuations using the 51 high quality undervalued stocks.
• Strengthen your income stream by focusing on reliable payers screened through the 12 dividend fortresses.
• Prioritise resilience by concentrating on companies with conservative risk profiles screened via the 71 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.